<DOC>
	<DOCNO>NCT00358631</DOCNO>
	<brief_summary>The objective evaluate efficacy safety two dos SSR149415 ( 250 mg 100 mg twice daily ) compare placebo escitalopram 10 mg daily outpatient major depressive disorder .</brief_summary>
	<brief_title>An Eight-Week Study Evaluating Efficacy Tolerability Two Doses SSR149415 Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Diagnosis major depressive disorder , define DSMIV criterion confirm semistructured MINI , recurrent episode . Total score le 24 MADRS . HAMD total score less 18 . Duration current depressive episode less 1 month great 2 year . Patients history presence bipolar disorder psychotic disorder . Patients alcohol dependence abuse substance dependence abuse past 12 month except nicotine caffeine dependence . Patients use follow prior entry Acute Phase : antipsychotic within 3 month , fluoxetine within 1 month , MAOIs within 2 week , antidepressant , anxiolytic , moodstabilizer ( lithium , anticonvulsant ) within 1 week except allow protocol . The investigator evaluate whether reason patient may participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>depression</keyword>
	<keyword>antidepressive agent</keyword>
	<keyword>control clinical trial</keyword>
</DOC>